Ascendis Wins FDA Approval For Rare Disease Therapy [Yahoo! Finance]
Ascendis Pharma A/S - American Depositary Shares (ASND)
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: Yahoo! Finance
Ascendis Pharma A/S shares are up during Monday's premarket session following the FDA's approval of Yuviwel (navepegritide; developed as TransCon CNP), the first and only once-weekly treatment for children with achondroplasia. FDA Approval The FDA approved Yuviwel, a prodrug designed to increase linear growth in children aged two years and older with achondroplasia, based on data from three randomized clinical trials. Achondroplasia is a rare genetic disorder causing dwarfism, characterized by short limbs, a normal-sized torso, and a large head. Ascendis Pharma plans to make Yuviwel available through prescribing physicians in the U.S. during the early part of the second quarter of 2026. Don't Miss: Explore the Fire-Safe Energy Storage Company With $185M in Contracted Revenue Fast Company Calls It a ‘Groundbreaking Step for the Creator Economy' — Investors Can Still Get In at $0.85/Share In November, Ascendis Pharma announced that pivotal week 52 results from its Appro
Show less
Read more
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASND
News
- Ascendis Pharma Details Early Q2 YUVIWEL Launch Plan, Pricing Tease at TD Cowen Conference [Yahoo! Finance]Yahoo! Finance
- Ascendis Pharma Maps 2026 U.S. Launch of Once-Weekly YUVIWEL After FDA Approval in Achondroplasia [Yahoo! Finance]Yahoo! Finance
- Ascendis Pharma A/S (ASND) was given a new $332.00 price target by Stifel Nicolaus.MarketBeat
- Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Royal Bank Of Canada.MarketBeat
- Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript [Seeking Alpha]Seeking Alpha
ASND
Earnings
- 2/11/26 - Miss
ASND
Sec Filings
- 3/4/26 - Form 144
- 3/4/26 - Form 144
- 3/2/26 - Form 144
- ASND's page on the SEC website